| scholarly article | Q13442814 |
| P50 | author | Michael D. Buck | Q55476775 |
| P2093 | author name string | David O'Sullivan | |
| Takuro Noguchi | |||
| Jing Qiu | |||
| Robert D Schreiber | |||
| Chih-Hao Chang | |||
| Qiongyu Chen | |||
| Gerritje J W van der Windt | |||
| Matthew M Gubin | |||
| Elena Tonc | |||
| Erika L Pearce | |||
| Jonathan D Curtis | |||
| Edward J Pearce | |||
| Mariel Gindin | |||
| P2860 | cites work | mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery | Q24302549 |
| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms | Q24534904 | ||
| Posttranscriptional control of T cell effector function by aerobic glycolysis | Q24606942 | ||
| Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma | Q24629841 | ||
| The PD-1 pathway in tolerance and autoimmunity | Q24633549 | ||
| mTOR signaling in growth control and disease | Q24634174 | ||
| Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation | Q24682128 | ||
| Fueling immunity: insights into metabolism and lymphocyte function | Q27025284 | ||
| T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment | Q38072512 | ||
| Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. | Q38091267 | ||
| Immune modulation in cancer with antibodies | Q38159801 | ||
| Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. | Q38218127 | ||
| Targeting T cell metabolism for therapy | Q38324388 | ||
| Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells | Q39239858 | ||
| Bioenergetic profile experiment using C2C12 myoblast cells | Q39614847 | ||
| Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells | Q41427795 | ||
| Alerting the immune system via stromal cells is central to the prevention of tumor growth | Q41913328 | ||
| Mouse cerebellar granule neurons arrest the proliferation of human and rodent astrocytoma cells in vitro | Q42804262 | ||
| Construction and characterization of a conditionally active version of the serine/threonine kinase Akt. | Q42829358 | ||
| Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation? | Q42941158 | ||
| PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients | Q47679044 | ||
| Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue. | Q49022924 | ||
| Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness. | Q50755650 | ||
| Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma. | Q51036583 | ||
| Inhibitory effect of tumor cell-derived lactic acid on human T cells | Q79666516 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| On the Origin of Cancer Cells | Q27861025 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| PD-1 and its ligands in tolerance and immunity | Q28131650 | ||
| Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion | Q28131654 | ||
| Inhibition of T cell proliferation by macrophage tryptophan catabolism | Q28142922 | ||
| Why do cancers have high aerobic glycolysis? | Q28290710 | ||
| T cell exhaustion | Q29620463 | ||
| Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine | Q33584867 | ||
| Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment | Q33606150 | ||
| Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages | Q34071063 | ||
| Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired | Q34080914 | ||
| The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation | Q34242691 | ||
| Indoleamine 2,3 dioxygenase and metabolic control of immune responses | Q34308495 | ||
| Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. | Q34412152 | ||
| The CD28 signaling pathway regulates glucose metabolism | Q34525357 | ||
| The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection | Q34734469 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| Progressive differentiation and selection of the fittest in the immune response | Q35014086 | ||
| Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients | Q35015778 | ||
| Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation | Q35242438 | ||
| Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. | Q35404457 | ||
| Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma | Q35815273 | ||
| Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth | Q35849703 | ||
| Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells | Q36365491 | ||
| Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy | Q36829161 | ||
| PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells | Q36890941 | ||
| HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation | Q36907933 | ||
| Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways. | Q36995837 | ||
| Creating immune privilege: active local suppression that benefits friends, but protects foes. | Q37026641 | ||
| Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting | Q37418530 | ||
| Diversity in CD8(+) T cell differentiation. | Q37508408 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1229-1241 | |
| P577 | publication date | 2015-08-27 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression | |
| P478 | volume | 162 |
| Q64062477 | 3D models in the new era of immune oncology: focus on T cells, CAF and ECM |
| Q37747153 | A Century of Radiation Therapy and Adaptive Immunity |
| Q44423833 | A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells |
| Q91965753 | A Humanized Bone Niche Model Reveals Bone Tissue Preservation Upon Targeting Mitochondrial Complex I in Pseudo-Orthotopic Osteosarcoma |
| Q49359410 | A Landscape of Metabolic Variation across Tumor Types. |
| Q64078967 | A Metabolism Toolbox for CAR T Therapy |
| Q47208178 | A New Perspective on the Heterogeneity of Cancer Glycolysis. |
| Q92541443 | A Tailored Multifunctional Anticancer Nanodelivery System for Ruthenium-Based Photosensitizers: Tumor Microenvironment Adaption and Remodeling |
| Q92424013 | A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress |
| Q64915632 | A four-DNA methylation biomarker is a superior predictor of survival of patients with cutaneous melanoma. |
| Q92932998 | A framework for advancing our understanding of cancer-associated fibroblasts |
| Q36184602 | A quantitative transcriptomic analysis of the physiological significance of mTOR signaling in goat fetal fibroblasts |
| Q91292051 | A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer |
| Q93196354 | A reactive metabolite as an immune suppressant |
| Q94526301 | A review of cancer immunotherapy: from the past, to the present, to the future |
| Q89070228 | A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade |
| Q89518345 | A20 targets PFKL and glycolysis to inhibit the progression of hepatocellular carcinoma |
| Q92534159 | ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer |
| Q64888866 | Acetate Promotes T Cell Effector Function during Glucose Restriction. |
| Q98665171 | Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy |
| Q92648113 | Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer |
| Q90635228 | Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells |
| Q39329596 | Adoptive T cell therapy: An overview of obstacles and opportunities. |
| Q90477829 | Advances and challenges in immunotherapy of small cell lung cancer |
| Q54978053 | Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. |
| Q99557471 | Allogeneic Vγ9Vδ2 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer |
| Q64935147 | Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death. |
| Q57478281 | An Apoptotic and Endosymbiotic Explanation of the Warburg and the Inverse Warburg Hypotheses |
| Q93384099 | An ecosystem framework for understanding and treating disease |
| Q49852238 | Analysis of 13 C and 14 C labeling in pyruvate and lactate in tumor and blood of lymphoma-bearing mice injected with 13 C- and 14 C-labeled pyruvate. |
| Q58774383 | Anti PD-1 treatment increases [F]FDG uptake by cancer cells in a mouse B16F10 melanoma model |
| Q48480477 | Anti-GITR therapy promotes immunity against malignant glioma in a murine model. |
| Q41930681 | Antigen Cross-Presentation and T-Cell Cross-Priming In Cancer Immunology And Immunotherapy |
| Q49546319 | Antitumor T cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. |
| Q89947934 | Anxiolytic Drug FGIN-1-27 Ameliorates Autoimmunity by Metabolic Reprogramming of Pathogenic Th17 Cells |
| Q92487103 | Association network analysis identifies enzymatic components of gut microbiota that significantly differ between colorectal cancer patients and healthy controls |
| Q41642058 | Augmentation of glycolytic metabolism by meclizine is indispensable for protection of dorsal root ganglion neurons from hypoxia-induced mitochondrial compromise |
| Q64103536 | Autophagy inhibition enhances PD-L1 expression in gastric cancer |
| Q49835162 | B-Cell Metabolic Remodeling and Cancer. |
| Q90685618 | B7-H1 agonists could prevent disseminated inflammation by desensitizing cell susceptibility to cytotoxic T-cells |
| Q37407636 | Beyond Genomics: Multidimensional Analysis of Cancer Therapy Resistance |
| Q90171477 | Bidirectional signals of PD-L1 in T cells that fraternize with cancer cells |
| Q39313207 | Biochemical Underpinnings of Immune Cell Metabolic Phenotypes |
| Q99212443 | Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines |
| Q60047537 | CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success |
| Q64235860 | CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment |
| Q97067646 | CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape |
| Q38622052 | CCCTC-Binding Factor Translates Interleukin 2- and α-Ketoglutarate-Sensitive Metabolic Changes in T Cells into Context-Dependent Gene Programs. |
| Q45204023 | CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells. |
| Q33671867 | CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells |
| Q38795935 | Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors? |
| Q98291350 | Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment |
| Q39168795 | Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch. |
| Q91656807 | Cancer Metabolism Drives a Stromal Regenerative Response |
| Q95277485 | Cancer Stem Cell Plasticity - A Deadly Deal |
| Q97883527 | Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure |
| Q101573919 | Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy |
| Q92659638 | Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses |
| Q97535503 | Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma |
| Q64285254 | Carbon Nanomaterials for Energy and Biorelated Catalysis: Recent Advances and Looking Forward |
| Q36789958 | Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions |
| Q33831578 | Cellular Stress in the Context of an Inflammatory Environment Supports TGF-β-Independent T Helper-17 Differentiation |
| Q28073524 | Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents |
| Q33650301 | Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response |
| Q41128052 | Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells |
| Q92052107 | Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma |
| Q64964164 | Chimeric antigen receptor T cell therapy for multiple myeloma. |
| Q37599491 | Cholesterol Synthetase DHCR24 Induced by Insulin Aggravates Cancer Invasion and Progesterone Resistance in Endometrial Carcinoma. |
| Q38662757 | Cholesterol metabolites and tumor microenvironment: the road towards clinical translation. |
| Q38764407 | Chromatin Remodeling Factor LSH Drives Cancer Progression by Suppressing the Activity of Fumarate Hydratase |
| Q37139928 | Chromatin remodeling factor LSH affects fumarate hydratase as a cancer driver |
| Q46011813 | Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk. |
| Q48227716 | Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. |
| Q26741974 | Clinical significance of T cell metabolic reprogramming in cancer |
| Q39160992 | Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma |
| Q36998864 | Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family |
| Q88010589 | Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma |
| Q40398428 | Combination therapy with L-arginine and α-PD-L1 antibody boosts immune response against osteosarcoma in immunocompetent mice |
| Q98771142 | Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1 |
| Q64060410 | Competition for nutrients and its role in controlling immune responses |
| Q92740760 | Competitive glucose metabolism as a target to boost bladder cancer immunotherapy |
| Q39138664 | Concise Review: An (Im)Penetrable Shield: How the Tumor Microenvironment Protects Cancer Stem Cells. |
| Q90629204 | Consensus guidelines for the definition, detection and interpretation of immunogenic cell death |
| Q64243032 | Control of the Antitumor Immune Response by Cancer Metabolism |
| Q37718304 | Correlation between anti-PD-L1 tumor concentrations and tumor-specific and nonspecific biomarkers in a melanoma mouse model |
| Q50634571 | Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. |
| Q36387235 | Costimulation Endows Immunotherapeutic CD8 T Cells with IL-36 Responsiveness during Aerobic Glycolysis |
| Q60935183 | Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors |
| Q92253219 | Critical role of AMPK in redox regulation under glucose starvation |
| Q92662855 | Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review |
| Q38779877 | Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy |
| Q56334016 | Deciphering T Cell Immunometabolism with Activity-Based Protein Profiling |
| Q50535288 | Dendritic cell vaccine induces antigen-specific CD8+ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. |
| Q37268993 | Depletion of FAP+ cells reduces immunosuppressive cells and improves metabolism and functions CD8+T cells within tumors |
| Q92344010 | Development of an In Vivo Retrodialysis Calibration Method Using Stable Isotope Labeling to Monitor Metabolic Pathways in the Tumor Microenvironment via Microdialysis |
| Q55255737 | Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. |
| Q100455189 | Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion |
| Q92105294 | Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate |
| Q63409308 | Diversity and environmental adaptation of phagocytic cell metabolism |
| Q55230769 | Drosophila as a Model System to Study Nonautonomous Mechanisms Affecting Tumour Growth and Cell Death. |
| Q99350221 | Dysfunction of CD8 + PD-1 + T cells in type 2 diabetes caused by the impairment of metabolism-immune axis |
| Q39272251 | Dysfunctional T cell metabolism in the tumor microenvironment |
| Q64083369 | Early assessment with F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab |
| Q39111174 | Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia |
| Q52596335 | Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q40745622 | Emerging concepts of T cell metabolism as a target of immunotherapy. |
| Q96128419 | Emerging role of mTOR in tumor immune contexture: Impact on chemokine-related immune cells migration |
| Q102211135 | Endoplasmic reticulum stress signals in the tumour and its microenvironment |
| Q39313554 | Energy metabolic pathways control the fate and function of myeloid immune cells |
| Q89701989 | Enforced PGC-1α expression promotes CD8 T cell fitness, memory formation and antitumor immunity |
| Q39249589 | Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel |
| Q37059878 | Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers |
| Q92306387 | Enhancing CAR T-cell therapy through cellular imaging and radiotherapy |
| Q45871848 | Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy |
| Q89517158 | Enhancing Chimeric Antigen Receptor T cell Efficacy in Solid Tumors |
| Q89157400 | Erika Pearce: Fitting metabolism and immunity together, to a T |
| Q47668429 | Establishment of an Extracellular Acidic pH Culture System |
| Q49217371 | Evaluation of Mir-224, Mir-215 and Mir-143 as Serum Biomarkers for HCV Associated Hepatocellular Carcinoma |
| Q38663576 | Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer |
| Q92096943 | Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment |
| Q42085843 | Exosomal tetraspanins mediate cancer metastasis by altering host microenvironment. |
| Q49330263 | Exosomes derived from B16F0 melanoma cells alter the transcriptome of cytotoxic T cells that impacts mitochondrial respiration. |
| Q51201669 | Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients. |
| Q94546984 | FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer |
| Q33918641 | Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate |
| Q57160050 | Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth |
| Q54234131 | Fatty acid metabolism in CD8+ T cell memory: Challenging current concepts. |
| Q40682960 | Feasibility of induced metabolic bioluminescence imaging in advanced ovarian cancer patients: first results of a pilot study |
| Q92156808 | Fibronectin in Cancer: Friend or Foe |
| Q39026430 | Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul |
| Q64113944 | Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma |
| Q47914208 | Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments. |
| Q47576047 | From Experiment to Theory: What Can We Learn from Growth Curves? |
| Q33834498 | From Krebs to clinic: glutamine metabolism to cancer therapy. |
| Q91871661 | From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions |
| Q92644570 | Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity |
| Q64230023 | Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines |
| Q41369044 | Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells |
| Q102059535 | Functional and metabolic dichotomy of murine γδ T cell subsets in cancer immunity |
| Q36236396 | GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma |
| Q38962203 | GRIM-19: A master regulator of cytokine induced tumor suppression, metastasis and energy metabolism |
| Q104570499 | Genetic alterations associated with 18F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma |
| Q26765438 | Genetics and biology of pancreatic ductal adenocarcinoma |
| Q50105512 | Germline polymorphism of interferon-lambda3 is clinically associated with progression of renal cell carcinoma. |
| Q64056689 | Glioblastoma Stem- Cells, Metabolic Strategy to Kill a Challenging Target |
| Q88544231 | Glucose Homeostasis Is Important for Immune Cell Viability during Candida Challenge and Host Survival of Systemic Fungal Infection |
| Q91810115 | Glucose Transporter 3 is Essential for the Survival of Breast Cancer Cells in the Brain |
| Q36988176 | Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy |
| Q104795077 | Glucose metabolism characteristics and TLR8-mediated metabolic control of CD4+ Treg cells in ovarian cancer cells microenvironment |
| Q40341736 | Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes |
| Q39230796 | Glutamine Metabolism in Cancer: Understanding the Heterogeneity |
| Q49798196 | Glutamine Synthetase: Localization Dictates Outcome. |
| Q86934742 | Glycolysis and EZH2 boost T cell weaponry against tumors |
| Q95327672 | Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment |
| Q38610039 | Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs |
| Q37713095 | Heterogeneity in Cancer Metabolism: New Concepts in an Old Field |
| Q58770679 | Hexokinase 2 is dispensable for T cell-dependent immunity |
| Q42376109 | Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. |
| Q47896076 | Homeostatic control of metabolic and functional fitness of Treg cells by LKB1 signalling. |
| Q52668325 | How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. |
| Q95832132 | Human cancer germline antigen-specific cytotoxic T cell-what can we learn from patient |
| Q42373852 | Hyperglycaemia does not affect antigen-specific activation and cytolytic killing by CD8+ T cells in vivo |
| Q90226833 | Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality |
| Q49725890 | Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment. |
| Q39456881 | Hypoxia-Inducible Factors: Master Regulators of Cancer Progression |
| Q93110790 | Hypoxia-inducible factors in CD4+ T cells promote metabolism, switch cytokine secretion, and T cell help in humoral immunity |
| Q37261189 | IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. |
| Q52641602 | IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner. |
| Q57285558 | IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity |
| Q41968203 | Identification of functional metabolic biomarkers from lung cancer patient serum using PEP technology |
| Q45160017 | Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening |
| Q37697844 | Identification of potential serum biomarkers for breast cancer using a functional proteomics technology |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q56889817 | Immuno-Oncology: Emerging Targets and Combination Therapies |
| Q90050590 | Immunometabolic Checkpoints of Treg Dynamics: Adaptation to Microenvironmental Opportunities and Challenges |
| Q39262779 | Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses |
| Q92803859 | Immunometabolic cross-talk in the inflamed heart |
| Q91945216 | Immunometabolism and natural killer cell responses |
| Q93204690 | Immunometabolism features of metabolic deregulation and cancer |
| Q26773266 | Immunometabolism governs dendritic cell and macrophage function |
| Q58802811 | Immunometabolism in cancer at a glance |
| Q92768544 | Immunometabolism: A new target for improving cancer immunotherapy |
| Q38624726 | Immunometabolism: Cellular Metabolism Turns Immune Regulator |
| Q92890513 | Immunomodulatory roles of nitric oxide in cancer: tumor microenvironment says "NO" to antitumor immune response |
| Q37722551 | Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells |
| Q58107915 | Immunosuppressive circuits in tumor microenvironment and their influence on cancer treatment efficacy |
| Q89633233 | Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications |
| Q37694431 | Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment |
| Q41810793 | Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer |
| Q91907452 | Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites |
| Q37746816 | In vivo Reprogramming of Cancer Metabolism by MYC. |
| Q83600759 | Inactivation of 3-hydroxybutyrate dehydrogenase type 2 promotes proliferation and metastasis of nasopharyngeal carcinoma by iron retention |
| Q41696827 | Inactivation of HMGCL promotes proliferation and metastasis of nasopharyngeal carcinoma by suppressing oxidative stress |
| Q88574458 | Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming |
| Q64093208 | Increased Akt-Driven Glycolysis Is the Basis for the Higher Potency of CD137L-DCs |
| Q61817205 | Increased PD-L1 expression in radioresistant HNSCC cell lines after irradiation affects cell proliferation due to inactivation of GSK-3beta |
| Q88301710 | Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy |
| Q64101621 | Increased glycolysis correlates with elevated immune activity in tumor immune microenvironment |
| Q33730033 | Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy |
| Q42129279 | Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment. |
| Q89621123 | Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors |
| Q90439939 | Influence on [18F]FDG uptake by cancer cells after anti-PD-1 therapy in an enforced-immune activated mouse tumor |
| Q47290509 | Informatics for cancer immunotherapy |
| Q38770333 | Inhibition of glycolysis by a novel EGFR/HER2 inhibitor KU004 suppresses the growth of HER2+ cancer |
| Q64238076 | Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation |
| Q48293633 | Inhibitors of the PD-1 Pathway in Tumor Therapy |
| Q50217779 | Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment. |
| Q46065433 | Innate sensing of cancer's non-immunologic hallmarks |
| Q97643738 | Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction |
| Q48173597 | Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. |
| Q97069628 | Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities |
| Q50043586 | Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. |
| Q54997338 | Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: Clinical and prognostic implications. |
| Q100992474 | Integrative immunogenomic analysis of gastric cancer dictates novel immunological classification and the functional status of tumor-infiltrating cells |
| Q33648885 | Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells |
| Q39155250 | Interplay between Immune Checkpoint Proteins and Cellular Metabolism. |
| Q63409314 | Itaconic acid mediates crosstalk between macrophage metabolism and peritoneal tumors |
| Q47294990 | JAK/STAT3-Regulated Fatty Acid β-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance |
| Q37359052 | L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity |
| Q58701330 | LDH-A regulates the tumor microenvironment via HIF-signaling and modulates the immune response |
| Q92410138 | Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment |
| Q90043560 | Lactate and Lactate Transporters as Key Players in the Maintenance of the Warburg Effect |
| Q90220303 | Lactate dehydrogenase: a marker of diminished antitumor immunity |
| Q63884168 | Lactate modulates CD4+ T-cell polarization and induces an immunosuppressive environment, which sustains prostate carcinoma progression via TLR8/miR21 axis |
| Q47600761 | Lactic acid alleviates stress: good for female genital tract homeostasis, bad for protection against malignancy |
| Q38725344 | Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling |
| Q52372679 | Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. |
| Q92882432 | Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics |
| Q37641678 | LncRNA ANRIL is up-regulated in nasopharyngeal carcinoma and promotes the cancer progression via increasing proliferation, reprograming cell glucose metabolism and inducing side-population stem-like cancer cells |
| Q58774468 | Loss of function of miR-342-3p results in MCT1 over-expression and contributes to oncogenic metabolic reprogramming in triple negative breast cancer |
| Q39027509 | Loss of monocyte chemoattractant protein-1 expression delays mammary tumorigenesis and reduces localized inflammation in the C3(1)/SV40Tag triple negative breast cancer model |
| Q64071901 | Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer |
| Q49806173 | Manganese Dioxide Coated WS2 @Fe3 O4 /sSiO2 Nanocomposites for pH-Responsive MR Imaging and Oxygen-Elevated Synergetic Therapy. |
| Q40097679 | Manipulating Glucose Metabolism during Different Stages of Viral Pathogenesis Can Have either Detrimental or Beneficial Effects |
| Q55209479 | Mathematical Modeling of the Function of Warburg Effect in Tumor Microenvironment. |
| Q98771234 | Mechanisms of Cancer Resistance to Immunotherapy |
| Q55060215 | Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. |
| Q91801415 | Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer |
| Q50089395 | Mechanisms regulating T-cell infiltration and activity in solid tumors. |
| Q90043581 | Melanoma Metabolism: Cell Survival and Resistance to Therapy |
| Q89640431 | Memory T cells delay the progression of atherosclerosis via AMPK signaling pathway |
| Q39313220 | MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells |
| Q96348555 | Met-Flow, a strategy for single-cell metabolic analysis highlights dynamic changes in immune subpopulations |
| Q50133232 | Metabolic Barriers to T Cell Function in Tumors. |
| Q61448742 | Metabolic Checkpoints in Differentiation of Helper T Cells in Tissue Inflammation |
| Q58797278 | Metabolic Checkpoints: Novel Avenues for Immunotherapy of Cancer |
| Q39265746 | Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. |
| Q90623679 | Metabolic Factors Contribute to T-cell Inhibition in the Ovarian Cancer Ascites |
| Q92736070 | Metabolic Fitness and Plasticity in Cancer Progression |
| Q39197674 | Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment |
| Q39286043 | Metabolic Instruction of Immunity. |
| Q39452100 | Metabolic Interactions in the Tumor Microenvironment |
| Q91656884 | Metabolic Plasticity and Epithelial-Mesenchymal Transition |
| Q90642651 | Metabolic Plasticity in Chemotherapy Resistance |
| Q50217787 | Metabolic Regulation of T Cell Immunity. |
| Q39418546 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy |
| Q88693147 | Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy |
| Q42339950 | Metabolic Reprogramming Mediated by the mTORC2-IRF4 Signaling Axis Is Essential for Macrophage Alternative Activation |
| Q64245167 | Metabolic Reprogramming in Breast Cancer and Its Therapeutic Implications |
| Q60046968 | Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies |
| Q91310907 | Metabolic Stress Triggers Immune Escape by Tumors |
| Q58750642 | Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1 |
| Q99595178 | Metabolic and epigenetic regulation of T-cell exhaustion |
| Q92932414 | Metabolic and functional reprogramming of myeloid-derived suppressor cells and their therapeutic control in glioblastoma |
| Q26765256 | Metabolic communication in tumors: a new layer of immunoregulation for immune evasion |
| Q98196854 | Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy |
| Q92578624 | Metabolic coordination of T cell quiescence and activation |
| Q48102749 | Metabolic exhaustion in infection, cancer and autoimmunity. |
| Q92664771 | Metabolic influence on macrophage polarization and pathogenesis |
| Q92023481 | Metabolic interventions in the immune response to cancer |
| Q38850162 | Metabolic regulation of immune responses: therapeutic opportunities |
| Q39143778 | Metabolic reprogramming and apoptosis sensitivity: defining the contours of a T cell response. |
| Q39378337 | Metabolic reprogramming in the tumour microenvironment: a hallmark shared by cancer cells and T lymphocytes |
| Q39343660 | Metabolic rewiring in mutant Kras lung cancer |
| Q47759599 | Metabolic strategies of melanoma cells: Mechanisms, interactions with the tumor microenvironment, and therapeutic implications. |
| Q64950563 | Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling. |
| Q40436359 | Metabolic tug-of-war in tumors results in diminished T cell antitumor immunity |
| Q26765348 | Metabolism Is Central to Tolerogenic Dendritic Cell Function |
| Q90854388 | Metabolism as a guiding force for immunity |
| Q46291182 | Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond |
| Q97424076 | Metabolism of immune cells in cancer |
| Q89980729 | Metabolism of pancreatic cancer: paving the way to better anticancer strategies |
| Q39367096 | Metabolism shapes the tumor microenvironment |
| Q88016005 | Metabolites, genome organization, and cellular differentiation gene programs |
| Q90214418 | Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects |
| Q53037025 | Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. |
| Q37288070 | MicroRNAs and PIWI-interacting RNAs in oncology |
| Q58796751 | Microenvironmental regulation of cancer cell metabolism: implications for experimental design and translational studies |
| Q94481939 | Mimicking tumor hypoxia and tumor-immune interactions employing three-dimensional in vitro models |
| Q93078150 | Mitochondria as central hub of the immune system |
| Q39689532 | Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming. |
| Q92296866 | Mitochondrial Integrity Regulated by Lipid Metabolism Is a Cell-Intrinsic Checkpoint for Treg Suppressive Function |
| Q47770635 | Mitochondrial Priming by CD28. |
| Q90413933 | Mitochondrial Redox Hubs as Promising Targets for Anticancer Therapy |
| Q64060146 | Mitochondrial Retrograde Signalling and Metabolic Alterations in the Tumour Microenvironment |
| Q39410087 | Mitochondrial control of immunity: beyond ATP. |
| Q33798098 | Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma |
| Q90860192 | Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance |
| Q57842307 | Mitochondrial metabolism and cancer |
| Q38996832 | Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway |
| Q55420715 | Monoacylglycerol lipase regulates cannabinoid receptor 2-dependent macrophage activation and cancer progression. |
| Q57232070 | Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma |
| Q92556947 | NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer |
| Q90733162 | NK Cell Metabolism and Tumor Microenvironment |
| Q60947027 | Natural Killer Cell Education Is Associated With a Distinct Glycolytic Profile |
| Q92637629 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy |
| Q92445830 | Neutrophil Metabolic Shift during their Lifecycle: Impact on their Survival and Activation |
| Q92344203 | New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies? |
| Q90644432 | New concepts in feedback regulation of glucose metabolism |
| Q90008739 | New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer |
| Q93002697 | New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota |
| Q44101088 | Notable advances 2015. |
| Q39347426 | Novel "Elements" of Immune Suppression within the Tumor Microenvironment |
| Q56888845 | Novel Effector Phenotype of Tim-3 Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients |
| Q86113118 | Nutrient Competition: A New Axis of Tumor Immunosuppression |
| Q39456875 | Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk |
| Q37689449 | Nutrient and Metabolic Sensing in T Cell Responses |
| Q38974085 | Nutrients and the microenvironment to feed a T cell army |
| Q90212537 | Obesity and CD8 T cell metabolism: Implications for anti-tumor immunity and cancer immunotherapy outcomes |
| Q39178061 | Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. |
| Q90721907 | Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia |
| Q37017190 | Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. |
| Q46272404 | Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. |
| Q34538613 | Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. |
| Q40124899 | PD-1 Checkpoint Blockade in Combination with an mTOR Inhibitor Restrains Hepatocellular Carcinoma Growth Induced by Hepatoma Cell-Intrinsic PD-1. |
| Q99550883 | PD-1 suppresses the maintenance of cell couples between cytotoxic T cells and target tumor cells within the tumor |
| Q47120629 | PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? |
| Q28075712 | PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations |
| Q99564986 | PD-L1 controls cancer pyroptosis |
| Q52731766 | PD-L1 inhibitors in the pipeline: Promise and progress. |
| Q41693775 | PD-L1 is an activation-independent marker of brown adipocytes |
| Q47101171 | PD-L1/PD-1: new kid on the "immune metabolic" block. |
| Q41714574 | PDL1 And LDHA act as ceRNAs in triple negative breast cancer by regulating miR-34a |
| Q64122894 | PD‑L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling |
| Q37547644 | PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance |
| Q90614041 | Pharmacological Targeting of GLUT1 to Control Autoreactive T Cell Responses |
| Q49788536 | Phenotypic and Functional Properties of Tumor-Infiltrating Regulatory T Cells. |
| Q92155161 | Phosphoenolpyruvate from Glycolysis and PEPCK Regulate Cancer Cell Fate by Altering Cytosolic Ca2 |
| Q92304285 | Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation |
| Q48306408 | Potential Utility of FDG PET-CT as a Non-invasive Tool for Monitoring Local Immune Responses |
| Q92921569 | Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage |
| Q90576088 | Precursor exhausted T cells: key to successful immunotherapy? |
| Q37196014 | Primary and metastatic tumor dormancy as a result of population heterogeneity |
| Q92617618 | Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity |
| Q88506865 | Programmed death ligand 1 promotes lymph node metastasis and glucose metabolism in cervical cancer by activating integrin β4/SNAI1/SIRT3 signaling pathway |
| Q37042232 | Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality |
| Q47094138 | Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients |
| Q39198154 | Prospects for combining targeted and conventional cancer therapy with immunotherapy |
| Q26752535 | Pyruvate Kinase M2: A Potential Target for Regulating Inflammation |
| Q46302218 | Reactive oxygen species (ROS) are a key determinant of cancer's metabolic phenotype |
| Q42198803 | Real-time quantitative analysis of metabolic flux in live cells using a hyperpolarized micromagnetic resonance spectrometer |
| Q30252210 | Recent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: Potential ways to control these functions |
| Q94503527 | Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion |
| Q99630278 | Reciprocal change in Glucose metabolism of Cancer and Immune Cells mediated by different Glucose Transporters predicts Immunotherapy response |
| Q39273837 | Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries |
| Q52725238 | Regulation and Function of the PD-L1 Checkpoint. |
| Q54952659 | Regulation of Immune Cell Functions by Metabolic Reprogramming. |
| Q39322285 | Regulation of Metabolic Activity by p53. |
| Q43166710 | Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells. |
| Q94461827 | Regulation of sister chromatid cohesion by nuclear PD-L1 |
| Q48231687 | Regulatory T cells trigger effector T cell DNA damage and senescence caused by metabolic competition |
| Q38928127 | Regulatory circuits of T cell function in cancer |
| Q92058622 | Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer |
| Q33917658 | Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? |
| Q59798737 | Resident-Memory T Cells in Tissue-Restricted Immune Responses: For Better or Worse? |
| Q92132117 | Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon? |
| Q38809776 | Reversing T-cell Dysfunction and Exhaustion in Cancer |
| Q33732986 | Revisiting the hallmarks of cancer |
| Q41934141 | Role of PD-1 in Immunity and Diseases |
| Q101216971 | Roles of mitochondria in the hallmarks of metastasis |
| Q37491480 | S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. |
| Q38700564 | STAT3 Induces Immunosuppression by Upregulating PD-1/PD-L1 in HNSCC. |
| Q47607473 | Secretory Autophagy in Cancer-Associated Fibroblasts Promotes Head and Neck Cancer Progression and Offers a Novel Therapeutic Target |
| Q89969652 | Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy |
| Q90286267 | Sepsis Immunometabolism: From Defining Sepsis to Understanding How Energy Production Affects Immune Response |
| Q37688926 | Serum depletion induced cancer stem cell-like phenotype due to nitric oxide synthesis in oncogenic HRas transformed cells |
| Q92002600 | Shedding New Light on Cancer Metabolism: A Metabolic Tightrope Between Life and Death |
| Q90589491 | Signaling networks in immunometabolism |
| Q47372804 | Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma |
| Q49989121 | Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. |
| Q39418532 | Similarities and Distinctions of Cancer and Immune Metabolism in Inflammation and Tumors |
| Q38645730 | Similarities in the Metabolic Reprogramming of Immune System and Endothelium |
| Q99637273 | Single-cell metabolic profiling of human cytotoxic T cells |
| Q90727444 | Starvation and Pseudo-Starvation as Drivers of Cancer Metastasis through Translation Reprogramming |
| Q26767514 | Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression |
| Q91981643 | Strategies to Interfere with Tumor Metabolism through the Interplay of Innate and Adaptive Immunity |
| Q39190194 | Strategies to Target Glucose Metabolism in Tumor Microenvironment on Cancer by Flavonoids |
| Q38872869 | Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers |
| Q64055421 | Stressed: The Unfolded Protein Response in T Cell Development, Activation, and Function |
| Q92404807 | Striking a Balance-Cellular and Molecular Drivers of Memory T Cell Development and Responses to Chronic Stimulation |
| Q99565366 | Study on metastasis inhibition of Kejinyan decoction on lung cancer by affecting tumor microenvironment |
| Q46259330 | Suppression of FIP200 and autophagy by tumor-derived lactate promotes naïve T cell apoptosis and affects tumor immunity. |
| Q38752567 | Suppression of Glut1 and Glucose Metabolism by Decreased Akt/mTORC1 Signaling Drives T Cell Impairment in B Cell Leukemia |
| Q89682571 | Surgical Wound Fluids from Patients with Breast Cancer Reveal Similarities in the Biological Response Induced by Intraoperative Radiation Therapy and the Radiation-Induced Bystander Effect-Transcriptomic Approach |
| Q99555096 | Systemic Immunometabolism: Challenges and Opportunities |
| Q90162757 | T Cell Activation Depends on Extracellular Alanine |
| Q55000833 | T Cell Calcium Signaling Regulation by the Co-Receptor CD5. |
| Q89967564 | T Cell Dysfunction and Exhaustion in Cancer |
| Q92405303 | T Cell Dysfunction in Cancer Immunity and Immunotherapy |
| Q52596337 | T Cell Dysfunction in Cancer. |
| Q97539453 | T Cell Metabolism in Cancer Immunotherapy |
| Q92932341 | T lymphocytes against solid malignancies: winning ways to defeat tumours |
| Q52625023 | T-Cell Dysfunction in Glioblastoma: Applying a New Framework. |
| Q59341026 | T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses |
| Q39183146 | T-cell Metabolism as a Target to Control Autoreactive T Cells in β-Cell Autoimmunity |
| Q38915095 | T-cell metabolism governing activation, proliferation and differentiation; a modular view |
| Q64100384 | TAMing pancreatic cancer: combat with a double edged sword |
| Q58586565 | TAp73-induced phosphofructokinase-1 transcription promotes the Warburg effect and enhances cell proliferation |
| Q91620971 | TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis |
| Q37277182 | TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies |
| Q92890188 | TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells |
| Q52649195 | TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy. |
| Q57815155 | TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy |
| Q52354472 | TUMOR CROSSTALK NETWORKS PROMOTE GROWTH AND SUPPORT IMMUNE EVASION IN PANCREATIC CANCER. |
| Q38872235 | Taming Tumor Glycolysis and Potential Implications for Immunotherapy |
| Q91536702 | Targeted Metabolic Reprogramming to Improve the Efficacy of Oncolytic Virus Therapy |
| Q60950041 | Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy |
| Q92642526 | Targeting Cellular Metabolism Modulates Head and Neck Oncogenesis |
| Q58694964 | Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers |
| Q91782554 | Targeting Glucose Metabolism to Enhance Immunotherapy: Emerging Evidence on Intermittent Fasting and Calorie Restriction Mimetics |
| Q58801754 | Targeting T Cell Metabolism for Improvement of Cancer Immunotherapy |
| Q90098490 | Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy |
| Q52661722 | Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. |
| Q91826248 | Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma |
| Q50026335 | Targeting immuno-metabolism to improve anti-cancer therapies. |
| Q39149196 | Targeting neoantigens to augment antitumour immunity |
| Q91598122 | Targeting the tumor microenvironment and T cell metabolism for effective cancer immunotherapy |
| Q38805897 | Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy |
| Q38710513 | Temperature induces significant changes in both glycolytic reserve and mitochondrial spare respiratory capacity in colorectal cancer cell lines |
| Q64237577 | The 'Achilles Heel' of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy |
| Q98237511 | The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination |
| Q60914167 | The Adaptive Complexity of Cancer |
| Q92074035 | The Binding of PD-L1 and Akt Facilitates Glioma Cell Invasion Upon Starvation via Akt/Autophagy/F-Actin Signaling |
| Q89965531 | The Emerging Roles of Endoplasmic Reticulum Stress in Balancing Immunity and Tolerance in Health and Diseases: Mechanisms and Opportunities |
| Q38718460 | The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors |
| Q88494418 | The Interface of Pancreatic Cancer With Diabetes, Obesity, and Inflammation: Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop |
| Q41615240 | The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti-PD-1 Response in Patients with Renal Cell Carcinoma |
| Q41340368 | The Lymphatic System: Integral Roles in Immunity |
| Q90043597 | The Metabolic Remodelling in Lung Cancer and Its Putative Consequence in Therapy Response |
| Q90705241 | The Metabolic Requirements of Th2 Cell Differentiation |
| Q39538318 | The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia. |
| Q49463699 | The Potential Role of circRNA in Tumor Immunity Regulation and Immunotherapy. |
| Q39130457 | The Principles of Engineering Immune Cells to Treat Cancer |
| Q61449923 | The Prognostic and Therapeutic Value of PD-L1 in Glioma |
| Q57789211 | The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity |
| Q90162934 | The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8+ T Cell Fitness and Functionality |
| Q39518049 | The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction |
| Q92642235 | The Tumor Microenvironment in Colorectal Cancer Therapy |
| Q39169603 | The Unique Molecular and Cellular Microenvironment of Ovarian Cancer |
| Q34509467 | The Warburg Effect: How Does it Benefit Cancer Cells? |
| Q57167592 | The big picture: exploring the metabolic cross-talk in cancer |
| Q38828825 | The biology and function of fibroblasts in cancer |
| Q49826396 | The biology and management of non-small cell lung cancer. |
| Q92086089 | The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer |
| Q52641713 | The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. |
| Q58561576 | The clinical role of the TME in solid cancer |
| Q38968957 | The convergence of senescence and nutrient sensing during lymphocyte ageing |
| Q49843616 | The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. |
| Q99565360 | The crosstalk between circular RNAs and the tumor microenvironment in cancer metastasis |
| Q47678849 | The diverse functions of the PD1 inhibitory pathway |
| Q58694628 | The elevated glutaminolysis of bladder cancer and T cells in a simulated tumor microenvironment contributes to the up-regulation of PD-L1 expression by interferon-γ |
| Q28079015 | The ever-expanding role of HIF in tumour and stromal biology |
| Q47205727 | The fibrotic tumor stroma |
| Q98946913 | The fuel and engine: The roles of reprogrammed metabolism in metastasis of primary liver cancer |
| Q95936578 | The future of cancer immunotherapy: microenvironment-targeting combinations |
| Q98665168 | The hidden side of PD-L1 |
| Q48181172 | The hypoxic tumour microenvironment |
| Q26745842 | The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints |
| Q47617054 | The impact of cellular metabolism on chromatin dynamics and epigenetics |
| Q60934870 | The impact of senescence-associated T cells on immunosenescence and age-related disorders |
| Q88159540 | The influence of hypoxia and IFN-γ on the proteome and metabolome of therapeutic mesenchymal stem cells |
| Q92314188 | The influence of microenvironment on tumor immunotherapy |
| Q39328710 | The interplay between metabolic remodeling and immune regulation in glioblastoma |
| Q57067759 | The intracellular signalosome of PD-L1 in cancer cells |
| Q39023597 | The intragraft microenvironment as a central determinant of chronic rejection or local immunoregulation/tolerance |
| Q89507027 | The metabolic axis of macrophage and immune cell polarization |
| Q36879974 | The multifaceted role of CD4(+) T cells in CD8(+) T cell memory |
| Q29694341 | The multifaceted roles of fatty acid synthesis in cancer |
| Q64100953 | The prognostic value of PKM2 and its correlation with tumour cell PD-L1 in lung adenocarcinoma |
| Q57022016 | The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells |
| Q92107874 | The role of Wnt signaling pathway in tumor metabolic reprogramming |
| Q52680707 | The role of the mitochondria and the endoplasmic reticulum contact sites in the development of the immune responses. |
| Q49853005 | The spectrum of T cell metabolism in health and disease. |
| Q94524554 | The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy |
| Q99711547 | To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors |
| Q92110394 | Topical Diclofenac Reprograms Metabolism and Immune Cell Infiltration in Actinic Keratosis |
| Q50217785 | Transcriptional Regulation of T Cell Metabolism Reprograming. |
| Q28077647 | Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity |
| Q92282117 | Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response |
| Q90043556 | Tumor Microenvironment - Selective Pressures Boosting Cancer Progression |
| Q64122311 | Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma |
| Q88748954 | Tumor cell-intrinsic PD-L1 promotes tumor-initiating cell generation and functions in melanoma and ovarian cancer |
| Q47678837 | Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma. |
| Q96167005 | Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints |
| Q39441385 | Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure |
| Q37409946 | Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity |
| Q38743564 | Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma. |
| Q30830664 | Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine |
| Q90746399 | Tumor-intrinsic CD47 signal regulates glycolysis and promotes colorectal cancer cell growth and metastasis |
| Q58611503 | Tumors sweeten macrophages with acids |
| Q47772621 | Tumour acidosis: from the passenger to the driver's seat. |
| Q86239752 | Tumour immunology: An exhausting metabolic competition |
| Q37627771 | Tumour microenvironment factors shaping the cancer metabolism landscape. |
| Q59799202 | Tumour-elicited neutrophils engage mitochondrial metabolism to circumvent nutrient limitations and maintain immune suppression |
| Q96945876 | Turning Cold into Hot: Firing up the Tumor Microenvironment |
| Q39130440 | Understanding the Intersections between Metabolism and Cancer Biology |
| Q52314225 | Unraveling the Complex Interplay Between T Cell Metabolism and Function. |
| Q37058110 | Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies |
| Q93229458 | Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity |
| Q54185869 | Warburg meets epigenetics. |
| Q37224595 | Warburg metabolism in tumor-conditioned macrophages promotes metastasis in human pancreatic ductal adenocarcinoma. |
| Q57491938 | mTOR Regulation of Glycolytic Metabolism in T Cells |
| Q93053344 | mTOR signalling and cellular metabolism are mutual determinants in cancer |
| Q38951050 | mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function |
| Q89540099 | miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen |
Search more.